Additional research by Zhou revealed that the TAP 1 gene is among the targeted genes of GLI-1/2 and that both GLI-1 and TAP 1 play roles in determining the sensitivity of HCC cells to therapeutics such as sorafenib, doxorubicin, and cisplatin [67]. The gene discussed is GLI1; the disease is hepatocellular carcinoma.